Emerging Protein Biomarkers for the Diagnosis or Prediction of Gestational Diabetes-A Scoping Review.
Emerging Protein Biomarkers for the Diagnosis or Prediction of Gestational Diabetes-A Scoping Review.
复制标题
DOI：
10.3390/jcm10071533
复制
发表时间：
2021-04-06
影响因子：
3.9
通讯作者：
O'Shea PM
中科院分区：
文献类型：
--
作者：
Bogdanet D;Reddin C;Murphy D;Doheny HC;Halperin JA;Dunne F;O'Shea PM
简介：妊娠期糖尿病 (GDM) 被定义为妊娠期间发病或初次识别的高血糖，其患病率与 2 型糖尿病 (T2DM) 和肥胖症的发病率同步上升。 GDM 对母亲和孩子都有短期和长期的影响。因此，有效识别所有病例并开始早期治疗、减少胎儿暴露于高血糖并减少与 GDM 相关的不良妊娠结局至关重要。因此，建议将 GDM 筛查作为常规妊娠护理的一部分。目前的筛查方法，即口服葡萄糖耐量试验（OGTT），是一项冗长、繁琐、不方便且重复性差的测试。 GDM 的及时诊断需要不需要空腹样本的新型生物标志物。本次范围审查的目的是强调和描述满足 GDM 诊断要求的新兴蛋白质生物标志物。材料和方法：本次范围界定审查是根据系统评价和荟萃分析的首选报告项目（PRISMA）进行范围界定审查指南，使用 Cochrane 对照试验中央注册库（CENTRAL）、护理与联合健康文献累积索引（CINAHL）、PubMed、Embase 和 Web of Science 进行双重筛选和提取过程。检索范围包括截至 2020 年 7 月文献中发表的所有文章。结果：在确定的 3519 篇原始数据库引用中，有 385 篇符合全文审查条件。其中，332 个 (86.2%) 被纳入范围界定审查，提供了总共 589 个与 GDM 诊断相关的生物标志物研究。鉴于确定的生物标志物数量较多，引入了三个事后标准来减少讨论的项目：我们仅选择在我们的搜索确定并在 2017-2020 年发表的文章中至少被引用 5 次的蛋白质生物标志物。应用这些标准后，总共确定了 15 种生物标志物，并随后进行审查和讨论。结论：这篇综述详细介绍了蛋白质生物标记物，这些蛋白质生物标记物已被研究找到适合 GDM 诊断的测试方法，并有可能取代当前 GDM 筛查方案中使用的 OGTT。正在进行的研究工作将继续寻找更准确、更实用的生物标志物，将 GDM 筛查和诊断带入 21 世纪。
Introduction: Gestational diabetes (GDM), defined as hyperglycemia with onset or initial recognition during pregnancy, has a rising prevalence paralleling the rise in type 2 diabetes (T2DM) and obesity. GDM is associated with short-term and long-term consequences for both mother and child. Therefore, it is crucial we efficiently identify all cases and initiate early treatment, reducing fetal exposure to hyperglycemia and reducing GDM-related adverse pregnancy outcomes. For this reason, GDM screening is recommended as part of routine pregnancy care. The current screening method, the oral glucose tolerance test (OGTT), is a lengthy, cumbersome and inconvenient test with poor reproducibility. Newer biomarkers that do not necessitate a fasting sample are needed for the prompt diagnosis of GDM. The aim of this scoping review is to highlight and describe emerging protein biomarkers that fulfill these requirements for the diagnosis of GDM. Materials and Methods: This scoping review was conducted according to preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines for scoping reviews using Cochrane Central Register of Controlled Trials (CENTRAL), the Cumulative Index to Nursing & Allied Health Literature (CINAHL), PubMed, Embase and Web of Science with a double screening and extraction process. The search included all articles published in the literature to July 2020. Results: Of the 3519 original database citations identified, 385 were eligible for full-text review. Of these, 332 (86.2%) were included in the scoping review providing a total of 589 biomarkers studied in relation to GDM diagnosis. Given the high number of biomarkers identified, three post hoc criteria were introduced to reduce the items set for discussion: we chose only protein biomarkers with at least five citations in the articles identified by our search and published in the years 2017–2020. When applied, these criteria identified a total of 15 biomarkers, which went forward for review and discussion. Conclusions: This review details protein biomarkers that have been studied to find a suitable test for GDM diagnosis with the potential to replace the OGTT used in current GDM screening protocols. Ongoing research efforts will continue to identify more accurate and practical biomarkers to take GDM screening and diagnosis into the 21st century.
登录
查看更多内容
DOI：
10.23750/abm.v91i1.7675
发表时间：
2020-03-19
期刊：
Acta bio-medica : Atenei Parmensis
影响因子：
--
作者：
Al-Ghazali MJ;Ali HA;Al-Rufaie MM
通讯作者：
Al-Rufaie MM
影响因子：
1.7
作者：
Ademoglu, Esra Nur;Gorar, Suheyla;Keskin, Muge;Carlioglu, Ayse;Ucler, Rifki;Erdamar, Husamettin;Culha, Cavit;Aral, Yalcin
通讯作者：
Aral, Yalcin
影响因子：
3.7
作者：
Barker G;Lim R;Georgiou HM;Lappas M
通讯作者：
Lappas M
影响因子：
4.1
作者：
Badon SE;Zhu Y;Sridhar SB;Xu F;Lee C;Ehrlich SF;Quesenberry CP;Hedderson MM
通讯作者：
Hedderson MM
影响因子：
7.2
作者：
通讯作者：
--